Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bavarian Nordic A/S (BVNRY)
:BVNRY
Holding BVNRY?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
0.57Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 09, 2018
|% Change Since: -8.16%
|Next Earnings Date:Aug 16, 2018
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in the Travel Health portfolio and Public Preparedness, with record orders for the coming year. However, there are challenges with specific vaccines and logistical issues impacting immediate revenue. The sentiment leans positive due to significant achievements and future prospects.Company Guidance
During the Q3 2024 earnings call for Bavarian Nordic, key guidance metrics were discussed, highlighting a successful year with significant growth in their Travel Health portfolio, outperforming revenue consensus. The company recorded strong sales in their Public Preparedness segment, particularly in response to the mpox health crisis, with DKK 2.4 billion in revenues already secured for the next year. Bavarian Nordic is also preparing for the launch of their new Chikungunya vaccine, with U.S. FDA and European EMA reviews underway, and approval anticipated in early 2025. Financially, the company expects a revenue range of DKK 5.4 to DKK 5.8 billion and an EBITDA between DKK 1.45 and DKK 1.7 billion for 2024, with current orders for 2025 already reaching DKK 2.4 billion.Strong Travel Health Portfolio Performance
Travel Health portfolio experienced significant growth, surpassing revenue consensus. Notably strong growth in rabies and TBE vaccines in the U.S. and Germany, with rabies reaching 79% market share in the U.S. and 95% in Germany.
Public Preparedness Success and Future Orders
Strong sales in the Public Preparedness segment due to mpox crisis, with secured orders of DKK 2.4 billion for next year. WHO prequalification for mpox vaccine, enabling distribution in Africa.
Chikungunya Vaccine Development
Chikungunya vaccine is under accelerated review by FDA and EMA, with expected approval in early 2025. Expansion of commercial presence in anticipation of the launch.
Strong Financial Performance
Revenue for the first 9 months reached DKK 3.6 billion with a 43% gross margin. EBITDA for the period was DKK 692 million.
---
BVNRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BVNRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 15, 2024 | $9.68 | $7.96 | -17.77% |
| Aug 22, 2024 | $12.28 | $13.52 | +10.10% |
| May 08, 2024 | $7.83 | $7.82 | -0.13% |
| Feb 21, 2024 | $8.35 | $8.07 | -3.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bavarian Nordic A/S (BVNRY) report earnings?
Bavarian Nordic A/S (BVNRY) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Bavarian Nordic A/S (BVNRY) earnings time?
Bavarian Nordic A/S (BVNRY) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BVNRY EPS forecast?
Currently, no data Available
---